Kaptopril Krka

Captopril, the active ingredient in Kaptopril Krka, is an ACE inhibitor presented as an oral tablet for oral use. It treats hypertension, heart failure, post‑myocardial infarction and diabetic nephropathy in adult patients. It is indicated for patients requiring blood pressure control and for those with cardiovascular complications where inhibition of the renin‑angiotensin system is beneficial.

GNH USA supplies Kaptopril Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation to support import and distribution in multiple regions.

Captopril is used to manage conditions related to the renin‑angiotensin system and cardiovascular disease.

Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. Heart failure: decreases afterload and improves symptoms and survival. Post‑myocardial infarction: limits ventricular remodeling and reduces mortality. Diabetic nephropathy: slows progression of renal impairment in patients with diabetes.

Captopril may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Cough: dry, persistent cough. - Taste disturbances: metallic or salty taste. - Rash: mild skin eruption. - Dizziness or light‑headedness. - Headache.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or airway. - Severe hypotension: marked drop in blood pressure, especially after first dose. - Neutropenia or leukopenia: low white blood cell count. - Liver dysfunction: elevated transaminases or hepatitis.

Before initiating Captopril therapy, several safety considerations should be reviewed.

Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. Renal function assessment: evaluate serum creatinine and eGFR, adjust dose if impaired. Electrolyte review: monitor potassium levels, especially if combined with potassium‑sparing agents. Pregnancy warning: avoid use in pregnancy (Category D) due to risk of fetal toxicity. Elderly caution: start with lower dose and titrate slowly in older patients. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Captopril can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren: concurrent use in diabetes or renal impairment may increase risk of renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause hyperkalaemia. - Dual ACE/ARB therapy: combined use can lead to severe hypotension and renal impairment.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: Captopril may increase lithium levels, risking toxicity. - Other antihypertensives (e.g., beta‑blockers, diuretics): may enhance blood pressure lowering, requiring dose adjustments.